Full Text View
Tabular View
No Study Results Posted
Related Studies
Vertebroplasty for the Treatment of Fractures Due to Osteoporosis
This study is ongoing, but not recruiting participants.
Study NCT00068822   Information provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First Received: September 10, 2003   Last Updated: April 8, 2009   History of Changes

September 10, 2003
April 8, 2009
April 2003
August 2009   (final data collection date for primary outcome measure)
Back-specific functional status using Roland Scale at the 1-month time frame [ Time Frame: Month 1 ] [ Designated as safety issue: Yes ]
Back-specific functional status using Roland Scale
Complete list of historical versions of study NCT00068822 on ClinicalTrials.gov Archive Site
Health status outcome using SF-36 [ Time Frame: Month 1 ] [ Designated as safety issue: Yes ]
Health status outcome using SF-36
 
Vertebroplasty for the Treatment of Fractures Due to Osteoporosis
Investigational Vertebroplasty Efficacy and Safety Trial (INVEST)

Vertebroplasty is a procedure used to stabilize broken vertebrae, the bones that form the spine. This study will evaluate the effectiveness of vertebroplasty for the treatment of fractures due to osteoporosis.

Spontaneous, atraumatic compression fractures due to osteoporosis occur in more than 700,000 patients per year. Pain associated with these fractures may be excruciating, but before the advent of percutaneous vertebroplasty, treatment options were limited. Analgesic medications, bed rest, and bracing have been the mainstays of treatment, but each of these therapies has substantial limitations.

Because of the dearth of viable treatment options for osteoporotic vertebral compression fractures, the practice of percutaneous vertebroplasty, which involves injection of polymethylmethacrylate (medical cement) into the fractured vertebra, has disseminated rapidly. However, evidence for the efficacy of percutaneous vertebroplasty is currently limited to uncontrolled, nonblinded, small case studies. Even though high rates of success are reported, with up to 90% of patients achieving substantial pain relief, these case studies have not accounted for numerous important potential biases, including the natural tendency for compression fractures to heal spontaneously, regression toward the mean (wherein patients seek medical attention when pain is maximum), and the placebo effect. This study will examine the clinical efficacy of percutaneous vertebroplasty for treatment of painful osteoporotic vertebral compression fractures.

Participants in this study will be randomly assigned to receive either percutaneous vertebroplasty or a sham procedure (placebo control group). Participants may have up to 2 spinal levels treated. Participants will be enrolled in the study for 1 year and will have study visits at entry and Months 1 and 12. There will also be phone visits at Days 1, 2, 3, and 14 and Months 3 and 6. After Month 1, crossover from the placebo group to the vertebroplasty group will be allowed.

Phase III
Interventional
Treatment, Randomized, Double Blind (Subject, Outcomes Assessor), Placebo Control, Crossover Assignment, Safety/Efficacy Study
  • Spinal Fractures
  • Osteoporosis
  • Device: Percutaneous vertebroplasty
  • Procedure: Placebo
  • Experimental: Participants will receive percutaneous vertebroplasty
  • Placebo Comparator: Participants will receive partial vertebroplasty without PMMA

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
294
August 2009
August 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed osteoporosis or osteopenia
  • Vertebral compression fracture in vertebrae T4 through L5
  • Pain not responsive to medical therapy

Exclusion Criteria:

  • Malignant tumor or spinal canal compromise
  • Local or systemic infection
  • Pregnancy
  • Hip fracture
Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00068822
David F. Kallmes, MD (PI), Mayo Clinic
R01 AR049373, NIAMS-096
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
 
Principal Investigator: David F. Kallmes, MD Mayo Clinic
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP